Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis, in Adults

NCT05887908 is registered in ClinicalTrials.gov with Meiji Seika Pharma Co., Ltd. as lead sponsor.

NCT NCT05887908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05887908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis, in Adults
Lead sponsor
Meiji Seika Pharma Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
May 23, 2023
Completion date
November 26, 2024
Enrollment
614 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

acute pyelonephritis, ap, complicated urinary tract infection, cuti